• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Corey Daniel claimed ownership of 671,470 shares (SEC Form 3) (Amendment)

    2/26/24 9:37:29 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials
    Get the next $PBAX alert in real time by email
    SEC FORM 3/A SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Corey Daniel

    (Last) (First) (Middle)
    CERO THERAPEUTICS HOLDINGS, INC.
    201 HASKINS WAY, SUITE 230

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    02/14/2024
    3. Issuer Name and Ticker or Trading Symbol
    CERO THERAPEUTICS HOLDINGS, INC. [ CERO ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Technical Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    02/16/2024
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 393,361 D
    Common Stock(1) 267,093 D
    Common Stock 3,399 I Elizabeth Corey(2)
    Common Stock(5) 273 I Elizabeth Corey(2)
    Common Stock 3,399 I Daniel Corey as legal guardian of Hannah Margaret Corey, a minor child(3)
    Common Stock(5) 273 I Daniel Corey as legal guardian of Hannah Margaret Corey, a minor child(3)
    Common Stock 3,399 I Daniel Corey as legal guardian of Owen Griffin Corey, a minor child(4)
    Common Stock(5) 273 I Daniel Corey as legal guardian of Owen Griffin Corey, a minor child(4)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Series A Convertible Preferred Stock 02/14/2024 (6) Common Stock 15,000 $10(6) D
    Explanation of Responses:
    1. Represents earnout shares, each of which consist of one share of the Issuer's Common Stock, subject to forfeiture if certain vesting conditions are not satisfied. The earnout shares vest as follows: (i) 15,050 shares shall vest if the volume weighted average price ("VWAP") of the Common Stock for at least 20 of any 30 consecutive trading days following February 14, 2024 equals or exceeds the lesser of (x) $12.50 or (y) 125% of the then applicable conversion price; (ii) 15,050 shares shall vest if the VWAP for at least 20 of any 30 consecutive trading days following February 14, 2024 equals or exceeds the lesser of (x) $15.00 or (y) 150% of the then applicable conversion price; (iii) 6,020 shares shall vest upon a change of control; and (iv) 241,748 shares shall vest upon the Issuer's submission of an IND application to the FDA. If the vesting conditions are not met prior to February 14, 2028, the earnout shares will be cancelled
    2. The reporting person is the spouse of Elizabeth Corey and has shared voting and disposition power with respect to the shares owned by Elizabeth Corey.
    3. The reporting person is the trustee of Daniel Corey as legal guardian of Hannah Margaret Corey, a minor child (the "Hannah Trust") and has sole voting and disposition power with respect to the shares owned by the Hannah Trust.
    4. The reporting person is the trustee of Daniel Corey as legal guardian of Owen Griffin Corey, a minor child (the "Owen Trust") and has sole voting and disposition power with respect to the shares owned by the Owen Trust.
    5. Represents earnout shares, each of which consist of one share of Common Stock, subject to forfeiture if certain vesting conditions are not satisfied. The earnout shares vest as follows: (i) 114 shares shall vest if the VWAP of the Common Stock for at least 20 of any 30 consecutive trading days following February 14, 2024 equals or exceeds the lesser of (x) $12.50 or (y) 125% of the then applicable conversion price; (ii) 114 shares shall vest if the VWAP for at least 20 of any 30 consecutive trading days following February 14, 2024 equals or exceeds the lesser of (x) $15.00 or (y) 150% of the then applicable conversion price; (iii) 45 shares shall vest upon a change of control. If the vesting conditions are not met prior to February 14, 2028, the earnout shares will be cancelled.
    6. Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date.
    Remarks:
    This amendment to the Form 3 originally filed on February 16, 2024 is being filed solely to correct an error in the number of securities beneficially owned directly by the reporting person.
    /s/ Charles Carter, attorney-in-fact 02/26/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PBAX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PBAX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PBAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination

    Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) ("PBAX") and CERo Therapeutics, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms ("CERo") today announced that their previously announced business combination has closed, resulting in CERo becoming a publicly-traded company. In connection with the consummation of the business combination, the combined public company was renamed "CERo Therapeutics Holdings, Inc." The shares of common stock of the combined public company have been approved for listing on the Nasdaq Global Market and are expected to commence trading under the ticker symbol "CERO" t

    2/14/24 4:48:00 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics

    CERo is an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Its lead product candidate is expected to enter clinical trials in 2024. Anticipated cash resources will fund the advancement of CERo's lead product candidate, CER-1236 to early clinical data in hematological oncology The transaction reflects a pre-money equity value of $50 million for CERo, pro forma equity capitalization of $145 million and is expected to provide up to $13.7 million held in trust, assuming no redemptions by current Phoenix stockholders and no additional capital raised Business combination expected to be completed

    6/5/23 8:00:00 AM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement

    SEATTLE, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis (GBA) and inflammatory disorders, and Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) (PBAX), a special purpose acquisition company sponsored by Phoenix Biotech Sponsor, LLC and formed for the purpose of acquiring or merging with one or more businesses, today announced the mutual termination of their previously announced business combination agreement due to current market conditions. "Intrinsic was encouraged by the positive feedback from prospective investors regarding the attractiveness of our novel and capital-efficient appro

    12/6/22 9:18:15 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    $PBAX
    SEC Filings

    View All

    Phoenix Biotech Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

    2/28/24 9:00:38 AM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    Phoenix Biotech Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Change in Shell Company Status, Financial Statements and Exhibits, Leadership Update, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year (Amendment)

    8-K/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

    2/27/24 8:27:59 AM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    SEC Form D filed by Phoenix Biotech Acquisition Corp.

    D - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

    2/23/24 5:13:07 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    $PBAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Corey Daniel claimed ownership of 671,470 shares (SEC Form 3) (Amendment)

    3/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

    2/26/24 9:37:29 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4 filed by Laporte Kathleen (Amendment)

    4/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

    2/21/24 5:57:09 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    Atwood Brian G acquired 248,735 shares (SEC Form 4) (Amendment)

    4/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

    2/21/24 5:55:44 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    $PBAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Phoenix Biotech Acquisition Corp. (Amendment)

    SC 13G/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

    2/22/24 9:06:12 AM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13D/A filed by Phoenix Biotech Acquisition Corp. (Amendment)

    SC 13D/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

    2/20/24 5:18:13 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G/A filed by Phoenix Biotech Acquisition Corp. (Amendment)

    SC 13G/A - PHOENIX BIOTECH ACQUISITION CORP. (0001870404) (Subject)

    2/8/24 12:31:58 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials